What is the recommended dosing regimen for valacyclovir?

Valacyclovir Dosing Recommendations

The dose of valacyclovir depends entirely on the specific indication being treated, ranging from 500 mg once daily for HSV suppression to 1 gram three times daily for herpes zoster.

Herpes Simplex Virus (HSV) Infections

Genital Herpes – Initial Episode

• 1 gram orally twice daily for 10 days 1
• Initiate within 48 hours of symptom onset for maximum efficacy 1

Genital Herpes – Recurrent Episodes

• 500 mg orally twice daily for 3 days 1
• Start at the first sign or symptom of an episode 1

Genital Herpes – Suppressive Therapy (Immunocompetent)

• For patients with ≥10 recurrences per year: 1 gram once daily 2, 1
• For patients with <10 recurrences per year: 500 mg once daily 2, 1
• The 500 mg once-daily dose is less effective in patients with very frequent recurrences 2
• Safety documented for up to 1 year of continuous use 2

Genital Herpes – Suppressive Therapy (HIV-Infected)

• For patients with CD4+ count ≥100 cells/mm³: 500 mg twice daily 2, 1
• Once-daily dosing is inadequate in HIV-infected patients; twice-daily dosing is mandatory 2

Genital Herpes – Transmission Reduction

• 500 mg once daily for the source partner (in patients with ≤9 recurrences per year) 1

Cold Sores (Herpes Labialis)

• 2 grams twice daily for 1 day, taken 12 hours apart 1
• Initiate at the earliest symptom (tingling, itching, or burning) 1
• Approved for patients ≥12 years of age 1

Mucocutaneous HSV (Adults and Adolescents)

• 1 gram orally twice daily 3
• No pediatric preparation exists; limited data on dosing in children 3

Herpes Zoster (Shingles)

Standard Dosing (Immunocompetent Adults)

• 1 gram orally three times daily for 7 days 4, 1
• Initiate within 72 hours of rash onset for optimal efficacy 4
• Continue until all lesions have completely scabbed, which may extend beyond 7 days 4
• Most effective when started within 48 hours of rash onset 1

Immunocompromised Patients

• For uncomplicated herpes zoster: Consider 1 gram three times daily, but may require higher doses or extended duration 4
• For disseminated or invasive disease: Switch to intravenous acyclovir 10 mg/kg every 8 hours 5, 4
• Oral valacyclovir may be inadequate in severely immunocompromised hosts 4

High-Dose Regimen (Research Evidence)

• 900 mg three times daily for 10 days showed superior efficacy in middle-aged and elderly patients compared to lower doses 6
• This dose significantly reduced pain scores and incidence of postherpetic neuralgia in patients ≥45 years 6

Chickenpox (Varicella)

Pediatric Dosing (Ages 2 to <18 Years)

• 20 mg/kg orally three times daily for 5 days 1
• Maximum dose: 1 gram three times daily 1
• Initiate at the earliest sign or symptom 1
• Not recommended for children <2 years due to lack of safety and efficacy data 1

Renal Dose Adjustments

Creatinine Clearance-Based Dosing

• CrCl 30–49 mL/min: No dose reduction needed for standard HSV suppression (500 mg daily) 2
• CrCl 30–49 mL/min (herpes zoster): 500 mg–1 gram every 12 hours 1
• CrCl 10–29 mL/min: 500 mg–1 gram every 24 hours 1
• CrCl <10 mL/min: 500 mg every 24 hours 1
• End-stage renal disease on hemodialysis: Approximately one-third of acyclovir is removed during a 4-hour dialysis session 1

Monitoring Requirements

• Baseline renal function (serum creatinine and creatinine clearance) must be assessed before initiating therapy 4
• For intravenous acyclovir or prolonged high-dose oral therapy: Monitor renal function weekly or twice weekly 5, 4
• Ensure adequate hydration to minimize nephrotoxicity risk 2, 4

Special Populations

Pregnancy

• Acyclovir is preferred over valacyclovir during pregnancy due to larger safety experience 2
• For serious VZV complications (e.g., pneumonia): Use intravenous acyclovir 4

Hepatic Impairment

• No dose adjustment required in patients with cirrhosis 1
• The rate but not extent of conversion to acyclovir is reduced 1

Critical Safety Considerations

Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS)

• Avoid doses of 8 grams per day in immunocompromised patients 2
• High-dose valacyclovir (8 g/day) has been associated with TTP/HUS in immunocompromised patients 2, 7
• This complication has not been reported at doses used for HSV suppression (≤2 g/day) 2

Treatment Failure and Resistance

• If lesions persist after 7–10 days of appropriate therapy, suspect acyclovir resistance 2, 5
• All acyclovir-resistant strains are also resistant to valacyclovir 2
• For confirmed resistance: Switch to intravenous foscarnet 40 mg/kg every 8 hours until clinical resolution 2, 5, 4
• Resistance rates remain <0.5% in immunocompetent patients but rise to 5–7% in immunocompromised hosts 2

Common Pitfalls to Avoid

• Do not use short-course (1–3 day) regimens designed for genital herpes to treat herpes zoster 5, 4
• Do not use topical acyclovir as sole therapy; it is substantially less effective than systemic treatment 2, 4
• Do not discontinue herpes zoster therapy at exactly 7 days if lesions are still forming or have not scabbed 4
• Do not use once-daily dosing for HIV-infected patients; twice-daily dosing is required 2

Laboratory Monitoring

Routine Suppressive Therapy

• No laboratory monitoring needed for patients with normal renal function receiving episodic or suppressive oral therapy 2, 5

High-Risk Patients

• Monitor renal function in patients with significant renal impairment, advanced age, or single kidney 4
• For intravenous therapy: Assess renal function at initiation and weekly (or twice weekly) throughout treatment 5, 4